3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
6
Recruiting
4
Completed
2
Withdrawn
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Adenocarcinoma
1
Interventions
Drug Therapy
107
Cisplatin
97
Radiotherapy
89
Carboplatin
87
Bevacizumab
79
Oxaliplatin
74
tislelizumab
68
Capecitabine
67
Cyclophosphamide
65
Gemcitabine
64
toripalimab
61
Paclitaxel
57
Specimen Handling
55
pembrolizumab
54
sintilimab
53
Surgical Procedures, Operative
52
anlotinib
49
Magnetic Resonance Spectroscopy
49
Fluorouracil
49
Immune Checkpoint Inhibitors
43
Blood Specimen Collection
42
130-nm albumin-bound paclitaxel
42
Standard of Care
39
camrelizumab
36
fludarabine
35
lenvatinib
34
Leucovorin
34
venetoclax
30
Radiosurgery
30
Immunotherapy
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
OTHER
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT07268794
2025-12-08
CONVERT-HB1
Fudan University
Phase 2
Not yet recruiting
112 enrolled